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Abstract
Introduction: Central Giant Cell Granuloma (CGCG) is a non-
neoplastic benign process, of unknown etiology, more common in 
children and young adults. When aggressive, the lesion may result in 
considerable bone destruction and deformation. Oral and Maxillofacial 
surgery strongly depends on the nature of injury and it may vary 
from more conservative to more aggressive approach. Case report: 
The aim of the present study is to report and analyze, a giant cell 
central lesion in a 7-year-old patient on the right side of mandible 
body treated by surgical enucleation, curettage, and maintenance of 
the tooth germs. Discussion: In less aggressive lesions, curettage 
followed by radiographic monitoring is the most widely suggested 
treatment choice. However, the “gold standard” for aggressive and 
deforming lesions would be en-bloc resection with a safety margin. 
Most revisions show recurrence rates of 15 to 20%, thus clinical 
monitoring is necessary at least one year after the intervention. 
Conclusion: After 12 months, panoramic radiograph and computed 
tomography indicated new bone formation and no recurrence. In 
addition, good healing of soft tissues and correct eruption of the 
teeth #42, #43 and #44 were observed. 
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Introduction
Central giant cell granuloma (CGCG) is 
considered a benign proliferative non-neoplastic 
process, of unknown etiology, more common in 
children and young adults aged less than 30 years 
(60% of cases) [2]. Jaffe first described CGCG in 
1953, as a “reparative fibrous dysplasia” of jaw 
bones. Studies suggest greater female involvement 
when compared to men (72.7% of cases in women) 
[7]. CGCG is typically reported as a slow-growing, 
painless lesion of the jaw that may cause a mass 
effect on surrounding tissues [2, 7].
Radiographically, CGCG has unilocular or 
multilocular radiolucent areas with irregular or 
relatively regular edges, having a predominance 
of small cases where the lesion is present in 
multiple loci in both the mandible and maxilla, 
and shows cortical bone expansion [21]. Considering 
the location, the highest number of recorded 
injuries reports the lower jaw as preferred site 
(twice frequently in mandible when compared to 
maxilla) [20]. Upon variation in biological behavior, 
CGCG is classified between aggressive and non-
aggressive, according to the presence of symptoms, 
duration, root resorption and recurrence rate. Both 
radiologic and histologic characteristics are critical 
to determinate response to therapy and clinical 
behavior. Radiographic features of aggressive 
lesions include rapid growth, cortical thinning or 
perforation, size greater than 5 cm, recurrence 
after surgery, tooth displacement or resorption. 
In addition, histologically, aggressive lesions show 
a large area occupied by giant cells, great size, 
greater nucleolar organization and high expression 
of CD34 adhesion factors [9, 27]. 
Martin et al. suggested that this lesion should 
be differentiated from brown tumor in association 
with hyperthyroidism. Because both diseases have 
identical clinical and histopathological features, 
PTH levels should be examined. No PTH deviation 
encourages us to determine CGCG diagnosis [24].
Treatment should be planned according to clinical 
signs and symptoms and can vary from simple 
curettage associated with conservative therapies to 
en-bloc resection [25]. However, recurrences rates 
after surgical intervention are reported to be higher 
than 70%. To minimize surgical morbidity, especially 
in children, medical treatments acting on tumor 
proliferation have been proposed [12]. However, 
there is no evidence suggesting any superiority for 
medical over surgical treatment [29]. 
Alternative and adjunctive CGCG treatments, 
such as intralesional steroid injections, are reported 
to be an effective alternative to surgery. Other 
studies, however, suggested a paradoxical effect, 
promoting growth of lesion in some patients. 
Calcitonin therapy, via intranasal sprays as well 
as subcutaneous injections, also has been used 
successfully in CGCG treatment. Calcitonin is a 
hormone produced by thyroid gland that inhibits 
bone resorption of multinucleated giant cells while 
lowering serum calcium levels and stimulating 
osteoblasts [26, 29]. 
A relatively new CGCG treatment modality 
is the use of systemic interferon alfa. Interferon 
mechanism of action remains unclear; however, its 
effect might be related to its antiangiogenic effect on 
aggressive vascular components of the lesion [16]. 
It was previously reported that interferon therapy 
alone has shown mixed results, since complete 
resolution to failure. However, the use of daily dose 
of interferon for an extended period together with 
conservative treatment has shown positive results 
and enabled preservation of teeth and other vital 
structures, which might have been sacrificed in 
traditional resections [16, 19]. This new therapy 
modality has different side effects and potentially 
serious toxicity, so its use has been restricted to 
patients whom conservative approaches have failed. 
Treatment with denosumab has also been 
described in literature. Denosumab is a IgG2 human 
monoclonal antibody type which targets the RANK/
RANKL system. RANKL is an essential mediator 
to function, formation, and osteoclast survival [30]. 
RANKL inhibition leads to activity reduction of 
CGCG aggressive osteoclast function. Some previous 
studies reported denosumab utilization to treat 
CGCG in children, showing a volume reduction as 
well as an ossification of the lesion. Side effects, 
on the other hand, were reported to be headaches, 
dorsal and extremities pain [30, 31]. 
Bisphosphonates had also been described to 
treat CGCG in childhood. Bisphosphonates are 
drugs used to treat osteoporosis due to inhibition 
of osteoclast activity. In 2009, Landesberg et 
al. and Chien et al. reported CGCG cases in 
children treated with Alendronate. It was observed 
in both cases a secondary reossification of the 
lesion and conservation of tooth germs, avoiding 
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surgery and large debridement. Nevertheless, oral 
bisphosphonates have been reported to increase 
osteonecrosis risk mainly when associated with 
tooth extractions [8, 18]. 
The most common surgical procedure to treat 
CGCG is the curettage or surgical en-bloc resection, 
also removing approximately 5 mm of adjacent 
healthy tissue [1, 13, 22, 34]. Due to high relapse 
rates, CGCG treatment is reported to be aggressive 
even in children, although an intermediate technique 
consisting in en-bloc resection with conservation 
of basilar board and/or posterior board have also 
been suggested [5]. The present study treatment 
choice was enucleation and curettage of lesion with 
conservation of tooth germs. 
Case report
Male patient, leukoderma, 7 years old, was 
referred to the Oral and Maxillofacial department 
of the Federal University of Parana (UFPR) with an 
important and visible facial asymmetry on the right 
side of the body region of mandible, with 8 months 
of evolution. Patient reported moderate pain in the 
region. Significant occlusal changes and swelling 
were observed. Permanent teeth were not erupted 
due to lesion interposition, blocking physiological 
eruption of affected teeth. 
Cone bea m tomog raphy showed bone 
fenestrations as well as cortical expansion and 
perforation. Panoramic radiograph showed a well-
described, unilocular lesion in intimate relationship 
with posterior tooth germ. 
Surgical treatment was chosen, consisting of 
removing the lesion through enucleation. To try to 
prevent recurrences, the team decided to conduct 
this removal with safety margin through osteotomy 
and removal of healthy tissue adjacent to lesion. 
Since the patient was young, we opted for a more 
conservative approach, so there would be no loss 
of the teeth involved. The tooth germs (#43, #44 
and #45) were maintained. Only the teeth #74 
and #75 were extracted. Suture of the region was 
conducted using vicryl. 
At 12-month follow-up appointment, new 
complementary exams, such as panoramic 
radiograph and cone beam computed tomography 
of head were taken. No relapses of the lesion were 
observed. Results of laboratory tests indicated bone 
formation on the site previously occupied by injury, 
and suggested an absence of recurrence. Good soft 
tissue healing and correct eruption of teeth #42, 
#43 and #44 was also observed.
Figure 1 – Pre-operative photographs. A) Important and 
visible facial asymmetry on the right side of the body 
region of mandible, with 8 months of evolution. Patient 
reported no pain in the region. B) Mandible basilar region. 
It is possible to observe asymmetry and discrepancy 
between the right and left sides. C) Significant occlusal 
changes and swelling were observed (figure 4). Permanent 
teeth were not erupted due to lesion interposition, 
blocking physiological eruption of affected teeth
Figure 2 – Pre-Operative Imaging. A) Panoramic radiograph 
showing a well-described, unilocular lesion in intimate 
relationship with posterior dental germ. B and C) Cone 
beam tomography showed bone fenestrations as well as 
cortical expansion and perforation. Figure B also shows 
the intimate relationship of tooth roots with the lesion. 
CBCT resources were also used to measure lesion size, 
classified as aggressive due to its size and evolution time
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Figure 3 – Surgical procedures. Lesion was curetted 
and osteotomy was also conducted with TOOTH germ 
preservation. No teeth were extracted during surgery, 
even those whose root were involved in the lesion
Figure 4 – One-year post-operative photograph. Patient 
presented no gross facial asymmetry. Basilar region 
of mandible with a different aspect and no clinical 
asymmetry sign
Figure 5 – One-year panoramic radiograph. No signs 
of relapses were observed. It is important to highlight 
that tooth germ preservation attempt were effective and 
the preserved teeth continued its physiologic eruption 
and are continuously being monitored until completely 
eruption
Discussion
Treatment modalities to central giant cell 
granuloma of the jaws are a dilemma, because 
it is hard to know which viable treatment is the 
best option for each patient. Although literature 
suggests higher CGCG prevalence in female (72.7% 
of cases) [33], this study reported a CGCG case in a 
young male patient of 7 years-old. Another decisive 
factor to determine the extent and predictability 
of treatment was the presence of tooth germs and 
the team’s effort to not involve them in surgical 
treatment. The boy’s legal responsible person was 
aware of all described methods currently used to 
treat the lesion. 
Corticosteroid protocol to treat CGCG has shown 
varied results, from complete remission of lesion to 
tumor growth in others. No randomized controlled 
trials of this treatment have been conducted to 
determine its efficacy [6, 31].
Even though different studies suggest success 
in isolated treatment with calcitonin therapy, 
there are others that indicate lack of response 
with intracutaneous injections and sometimes, 
progression of lesion after one-year treatment 
[25-27]. The only randomized controlled trial 
on CGCG calcitonin treatment also showed no 
complete remissions [20]. One possible reason 
why calcitonin therapy CGCG is effective for some 
lesions and not for others might rely on the fact 
that the expression of calcitonin receptors may 
vary from different populations. In one study, 41 
specimens were analyzed and only 23 were reported 
to be positive to the receptor. A gold standard to 
determine whether calcitonin therapy would be 
effective includes immunohistochemical staining for 
calcitonin receptors protocols of biopsy specimens 
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to determine the therapy course. We did not have 
our specimen stained, however it is expected that 
more surgeons and clinicians have the staining 
performed [32].
Treatment with interferon has shown positive 
results in multiple case reports. Most part of cases 
combines this therapy with curettage with success 
and complete lesion relapse [17]. One case reported 
interferon therapy effective as monotherapy [10]. 
Other studies however, reported a decrease in the 
size of the lesion but not total relapse. The theory 
that encourages interferon protocol utilization is that 
it may be more effective and beneficial to aggressive 
types of CGGCs, as interferon is an antiangiogenic 
medication and more aggressive CGCGs have a 
stronger ratio of vascularization when compared 
to indolent lesions [10, 17]. Although there are 
promising results in the use of interferon protocol 
to treat aggressive CGCGs, there are harmful side 
effects that must be considered before applying 
the use of this medication, such as bone marrow 
suppression and hair loss. In addition, interferon 
therapy is not used as first linage therapy it remains 
as savage procedure [14].
In June 2013, FDA approved using denosumab 
to treat CGCG in adults and some adolescents. 
According to FDA the intent of this therapy for those 
patients is to avoid severe morbidity of surgical 
procedures. Denosumab mechanism of action relies 
on inhibiting the receptor activator of nuclear factor 
kappa-B (RANK) and RANK ligand\osteoprotegerin 
(OPG) interaction, resulting in inhibition of osteoclast 
activity [30]. Schreuder et al. reported a CGCG case 
of a young adult patient treated with Denosumab 
subcutaneous injections for 12 months after failing 
calcitonin and interferon therapies. They concluded 
that using Denosumad to treat aggressive CGCG 
lesions that did not respond to other therapies were 
effective, however, more studies are needed before 
it becomes a mainstay therapy. The most serious 
side effect of denosumab is medication-related jaw 
osteonecrosis and osteomyelitis [28]. This has not 
been seen in the treatment of CGCG to date, but 
a thorough dental assessment before beginning of 
this medication regimen is recommended.
Surgery has always been considered the 
traditional treatment and it is still the most accepted 
one. On the other hand, some authors disagree on 
the surgery type performed as well as its indications 
[9]. When teeth are associated with lesion, they are 
suggested to be retained if they do not compromise 
the removal of the lesion in question [3]. CGCGs 
have traditionally been treated surgically. Common 
therapy is curettage or resection. Eisenbud et al 
advocated curettage or curettage plus peripheral 
osteotomy with maintenance of tooth germs for 
treatment of CGCG in children. He also suggested 
recurrence to range from 16% to 49%. Lesion 
relapses when they are removed via curettage were 
suggested to be treated with peripheral osteotomy 
and bone resection [1]. 
En-bloc resection might provide the greatest 
certainty of cure. Bataineh et al. conducted a study 
with 18 patients with aggressive CGCG, treated 
with en-bloc resection with 5 mm health tissue 
margin. Only one patient had lesion recurrence. 
Most authors agree that for child and growing 
patients, more conservative surgery is the only 
applicable strategy for maintaining the tooth germs 
to let them erupt physiologically [4]. In general, 
destructive surgery (en-bloc surgical resection with 
5 mm margins) seems to be the safest option for 
the control of recurrences but it may result in 
facial deformities, which are obviously of great 
concern. Due to aggressive characteristics observed 
in the patient reported in our case, we opted for 
conservative surgical treatment of CGCG through 
curettage and bone osteotomy, with success, without 
generate gross facial deformities and no relapse 12 
months after surgery. 
Conclusion
Different treatment modalities have been 
proposed to treat CGCG and each case must be 
analyzed differently regarding clinical features and 
lesion presentation, pathological behavior as well 
as patient conditions and limitations. CGCG in 
childhood must be looked with special attention, 
because invasive surgical procedures may cause 
facial deformities. 
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